Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register
Authors:
- 9 July 2020
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 37 (8) , 617-626
Abstract
Objective The objective of this study was to compare the efficacy and safety of rituximab in older vs younger patients with rheumatoid arthritis. Methods Data on 367 patients with rheumatoid arthritis treated with rituximab in the Norwegian Disease-Modifying Antirheumatic Drug (NOR-DMARD) register were analysed, comparing patients aged ≥ 65 years (n = 91) with patients aged < 65 years (n = 276). Drug survival was compared using a Kaplan–Meier analysis and Cox proportional hazard models. Disease activity, as assessed by the Disease Activity Score based on 28 joints and erythrocyte sedimentation rate (DAS28-ESR) and the Simplified Disease Activity Index, was analysed with linear mixed models. The occurrence of adverse events was analysed by quasi-Poisson regression models. Results Drug survival was similar in the two age groups. The proportion of patients who remained taking rituximab over 2 years was 72% in those under aged 65 years vs 74% in those aged ≥ 65 years. No statistically significant association with age was found for drug survival in either the unadjusted (hazard ratio 1.13, p = 0.65) or adjusted Cox proportional hazard analyses for the model with DAS28-ESR as a confounder (effect size 1.11, p = 0.73). Models including the Simplified Disease Activity Index instead of DAS28-ESR yielded similar results. Age was furthermore not significantly associated with disease activity over time, although there was a tendency towards a poorer response in older patients. In the older age group, there was a higher incidence of pneumonia (107 vs 51 per 1000 patient-years) and other serious infections (142 vs 66 per 1000 patient-years). Conclusions Rituximab is a reasonable therapeutic option for older patients with rheumatoid arthritis although vigilance is needed with regard to the infection profile. Trial Registration ClinicalTrials.gov Identifier: NCT01581294.Keywords
This publication has 32 references indexed in Scilit:
- Pneumonia burden in elderly patients: a classification algorithm using administrative dataBMC Infectious Diseases, 2013
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnnals of the Rheumatic Diseases, 2007
- Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population‐based cohort studyArthritis Care & Research, 2007
- Risk???:???Benefit Profile of Etanercept in??Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or??Psoriatic ArthritisDrugs & Aging, 2007
- Long term safety of etanercept in elderly subjects with rheumatic diseasesAnnals of the Rheumatic Diseases, 2006
- Survival and safety of treatment with infliximab in the elderly populationRheumatology, 2005
- Epidemiology and Unique Aspects of Aging and Infectious DiseasesClinical Infectious Diseases, 2000
- Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaireArthritis & Rheumatism, 1983